[go: up one dir, main page]

LUC00032I1 - - Google Patents

Info

Publication number
LUC00032I1
LUC00032I1 LU00032C LUC00032C LUC00032I1 LU C00032 I1 LUC00032 I1 LU C00032I1 LU 00032 C LU00032 C LU 00032C LU C00032 C LUC00032 C LU C00032C LU C00032 I1 LUC00032 I1 LU C00032I1
Authority
LU
Luxembourg
Prior art keywords
tumor
cells
patient
immune response
cell type
Prior art date
Application number
LU00032C
Other languages
English (en)
Original Assignee
Univ Georgetown
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26733894&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LUC00032(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Georgetown filed Critical Univ Georgetown
Publication of LUC00032I1 publication Critical patent/LUC00032I1/fr
Publication of LUC00032I2 publication Critical patent/LUC00032I2/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/763—Herpes virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/208—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0331—Animal model for proliferative diseases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16632—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16641—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16643—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/108—Plasmid DNA episomal vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
LU00032C 1997-08-12 2017-08-09 LUC00032I2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5514297P 1997-08-12 1997-08-12
US09/064,174 US6379674B1 (en) 1997-08-12 1998-04-22 Use of herpes vectors for tumor therapy
EP98939886A EP1003533B1 (fr) 1997-08-12 1998-08-12 Utilisation de vecteurs d'herpes pour le traitement de tumeurs

Publications (2)

Publication Number Publication Date
LUC00032I1 true LUC00032I1 (fr) 2017-08-10
LUC00032I2 LUC00032I2 (fr) 2017-10-11

Family

ID=26733894

Family Applications (1)

Application Number Title Priority Date Filing Date
LU00032C LUC00032I2 (fr) 1997-08-12 2017-08-09

Country Status (11)

Country Link
US (5) US6379674B1 (fr)
EP (2) EP1003533B1 (fr)
JP (2) JP5078195B2 (fr)
AT (1) ATE342724T1 (fr)
AU (1) AU8824998A (fr)
CA (1) CA2301327C (fr)
DE (1) DE69836219T2 (fr)
ES (2) ES2627764T3 (fr)
LU (1) LUC00032I2 (fr)
PT (1) PT1776957T (fr)
WO (1) WO1999007394A1 (fr)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6379674B1 (en) * 1997-08-12 2002-04-30 Georgetown University Use of herpes vectors for tumor therapy
JP2003535565A (ja) * 1998-12-31 2003-12-02 アーチ ディベロプメント コーポレイション 新生物疾患の治療に有用な組換え単純ヘルペスウイルス
AU6120600A (en) * 1999-06-08 2000-12-28 Uab Research Foundation Herpes simplex virus expressing foreign genes and method for treating cancers therewith
US6764675B1 (en) 1999-06-08 2004-07-20 The Uab Research Foundation Herpes simplex virus expressing foreign genes and method for treating cancers therewith
US6723316B2 (en) * 1999-12-22 2004-04-20 Onyx Pharmaceuticals, Inc. Herpes simplex virus-1 Glycoprotein C mutants for treating unwanted hyperproliferative cell growth
US7063835B2 (en) * 2000-01-21 2006-06-20 Biovex Limited Virus strains
EP1381280B1 (fr) 2001-03-27 2011-05-11 Catherex, Inc. Vecteurs viraux et utilisation de ces derniers dans des methodes therapeutiques
WO2002087625A1 (fr) * 2001-05-02 2002-11-07 Ramot At Tel-Aviv University Ltd. Vecteurs du virus de l'herpes oncolytique composite
DE10131148A1 (de) * 2001-06-28 2003-01-16 I P L Internat Pharmaceutics L Xenogene Oligo- oder/und Polyribonukleotide als Mittel zur Behandlung von malignen Tumoren
CA2476724A1 (fr) * 2002-03-01 2003-09-12 Sloan-Kettering Institute For Cancer Research Prevention de recurrence et de metastase cancereuses
US8216564B2 (en) * 2002-05-02 2012-07-10 Ramot At Tel-Aviv University Ltd. Composite oncolytic herpes virus vectors
JP2004099584A (ja) * 2002-05-02 2004-04-02 Keio Gijuku Ｈｓｖを用いた抗腫瘍剤
US7655459B2 (en) 2004-03-31 2010-02-02 Tomoki Todo Enhancer of anticancer activity in viral therapy and method of preventing or treating cancer
US7731952B2 (en) * 2004-06-24 2010-06-08 New York University Avirulent oncolytic herpes simplex virus strains engineered to counter the innate host response
WO2009052426A2 (fr) * 2007-10-17 2009-04-23 The Ohio State University Virus oncolytique
US8450106B2 (en) * 2007-10-17 2013-05-28 The Ohio State University Research Foundation Oncolytic virus
KR100905419B1 (ko) 2008-09-11 2009-07-02 연세대학교 산학협력단 세스퀴테르펜 유도체의 용도
EP2687609B1 (fr) 2008-11-10 2017-01-04 The United States of America, as represented by The Secretary, Department of Health and Human Services Méthode de traitement de tumeurs solides
US9150926B2 (en) 2010-12-06 2015-10-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Diagnosis and treatment of adrenocortical tumors using human microRNA-483
SMT201900033T1 (it) * 2011-09-08 2019-02-28 Univ New York Virus herpes simplex oncolitico e suoi usi terapeutici
KR20230107375A (ko) 2014-12-18 2023-07-14 암젠 인크 안정한 동결된 단순 포진 바이러스 제제
WO2016205429A1 (fr) 2015-06-15 2016-12-22 New York University Méthode de traitement utilisant des virus oncolytiques
EP3324988B1 (fr) 2015-07-20 2021-03-03 Virttu Biologics Limited Utilisation d'un virus herpes simplex oncolytique en combinaison avec un inhibiteur de point de contrôle immunitaire, dans le traitement du cancer
ES3041885T3 (en) 2016-01-08 2025-11-17 Replimune Ltd Engineered virus
US10888594B2 (en) 2016-05-30 2021-01-12 National University Corporation Tottori University Genetically engineered vaccinia viruses
EP3480307B1 (fr) * 2016-05-30 2021-06-23 Astellas Pharma Inc. Nouveau virus de la vaccine génétiquement modifié
US20190336552A1 (en) 2016-05-30 2019-11-07 Astellas Pharma Inc. Genetically engineered vaccinia viruses
EP3490583B1 (fr) * 2016-08-01 2023-11-29 Virogin Biotech Canada Ltd Vecteurs de virus de l'herpès simplex oncolytique exprimant des molécules stimulatrices du système immunitaire
GB201700350D0 (en) 2017-01-09 2017-02-22 Replimune Ltd Altered virus
JP2020510050A (ja) 2017-03-15 2020-04-02 アムジエン・インコーポレーテツド がんを治療するための、腫瘍溶解性ウイルスの単独又はチェックポイント阻害剤との組み合わせでの使用
TW201900193A (zh) 2017-04-28 2019-01-01 美商默沙東藥廠 用於癌症治療之生物標記物
SI3661954T1 (sl) 2017-08-03 2022-05-31 Amgen Inc. Muteini interlevkina-21 in postopki zdravljenja
TW201912173A (zh) 2017-08-07 2019-04-01 美商安進公司 三陰性乳癌或結腸直腸癌伴隨肝轉移之治療
ES2985118T3 (es) 2017-09-08 2024-11-04 Amgen Inc Inhibidores de KRAS G12C y métodos de uso de los mismos
UY38049A (es) 2018-01-12 2019-07-31 Amgen Inc Anti-pd-1 anticuerpos y métodos de tratamiento
CN108635380A (zh) 2018-04-13 2018-10-12 北京唯源立康生物科技有限公司 重组溶瘤病毒组合物及其在制备用于治疗肿瘤的药物中的应用
CA3113965A1 (fr) 2018-09-26 2020-04-02 Astellas Pharma Inc. Therapie anticancereuse dans laquelle un virus de la vaccine oncolytique et un inhibiteur des points de controle immunitaire sont utilises en combinaison, et composition pharmaceu tique et medicament combine utilises dans celle-ci
MX2021007639A (es) 2018-12-27 2021-08-11 Amgen Inc Formulaciones de virus liofilizadas.
US20220090133A1 (en) 2019-03-05 2022-03-24 Amgen Inc. Use of oncolytic viruses for the treatment of cancer
TW202102543A (zh) 2019-03-29 2021-01-16 美商安進公司 溶瘤病毒在癌症新輔助療法中之用途
US20230227847A1 (en) * 2020-05-27 2023-07-20 Universität Zürich Viral vectors expressing therapeutic proteins specifically in myeloid cells and microglia
CA3213789A1 (fr) 2021-04-02 2022-10-06 Krystal Biotech, Inc. Vecteurs viraux pour la therapie du cancer

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL9001828A (nl) 1990-08-15 1992-03-02 Centraal Diergeneeskundig Inst Werkwijze voor het wijzigen van het cel-, weefsel- of gastheertropisme van een microoerganisme; aldus verkregen gerecombineerd microorganisme en toepassing daarvan in de geneeskunde en diergeneeskunde.
EP0573564A1 (fr) 1991-02-22 1993-12-15 Massachusetts Institute Of Technology Expression de la nestine comme indicateur de tumeurs neuroepitheliales
WO1993019591A1 (fr) * 1992-03-31 1993-10-14 Arch Development Corporation Procedes et compositions utilises en therapie genique et pour la therapie contre les tumeurs et les infections virales, et pour la prevention de la mort cellulaire programmee (apoptose)
US5639656A (en) * 1994-03-31 1997-06-17 Medical College Of Hampton Road Antibodies reactive with biological markers of benign prostate hyperplasia
US5571515A (en) 1994-04-18 1996-11-05 The Wistar Institute Of Anatomy & Biology Compositions and methods for use of IL-12 as an adjuvant
US5585096A (en) 1994-06-23 1996-12-17 Georgetown University Replication-competent herpes simplex virus mediates destruction of neoplastic cells
US6699468B1 (en) * 1994-06-23 2004-03-02 Georgetown University Replication-competent herpes simplex virus mediates destruction of neoplastic cells
US5728379A (en) * 1994-06-23 1998-03-17 Georgetown University Tumor- or cell-specific herpes simplex virus replication
JP3822261B2 (ja) * 1994-09-09 2006-09-13 財団法人癌研究会 癌の遺伝子治療剤
GB9511101D0 (en) 1995-06-01 1995-07-26 British Tech Group Magnetic coil
WO1997026904A1 (fr) * 1996-01-25 1997-07-31 Medical Research Council Traitement de cancer non neuronal a l'aide d'un mutant de hsv
US6051428A (en) * 1997-03-21 2000-04-18 Sloan-Kettering Institute For Cancer Research Rapid production of autologous tumor vaccines
US6379674B1 (en) * 1997-08-12 2002-04-30 Georgetown University Use of herpes vectors for tumor therapy
EP1381280B1 (fr) * 2001-03-27 2011-05-11 Catherex, Inc. Vecteurs viraux et utilisation de ces derniers dans des methodes therapeutiques

Also Published As

Publication number Publication date
CA2301327A1 (fr) 1999-02-18
DE69836219D1 (de) 2006-11-30
LUC00032I2 (fr) 2017-10-11
EP1776957A2 (fr) 2007-04-25
EP1776957B1 (fr) 2017-03-01
AU8824998A (en) 1999-03-01
CA2301327C (fr) 2011-06-14
US8361978B2 (en) 2013-01-29
JP5078195B2 (ja) 2012-11-21
ES2276470T3 (es) 2007-06-16
EP1003533A1 (fr) 2000-05-31
US6379674B1 (en) 2002-04-30
US9827307B2 (en) 2017-11-28
EP1776957A3 (fr) 2009-06-24
EP1003533B1 (fr) 2006-10-18
JP2001513508A (ja) 2001-09-04
US20050232907A1 (en) 2005-10-20
ES2627764T3 (es) 2017-07-31
PT1776957T (pt) 2017-06-12
JP2012067114A (ja) 2012-04-05
US20020127246A1 (en) 2002-09-12
HK1028560A1 (en) 2001-02-23
US20130224243A1 (en) 2013-08-29
WO1999007394A1 (fr) 1999-02-18
US20090053178A1 (en) 2009-02-26
ATE342724T1 (de) 2006-11-15
DE69836219T2 (de) 2007-08-23

Similar Documents

Publication Publication Date Title
LUC00032I1 (fr)
EP1192948A3 (fr) Utilisation d'un mutant HSV dans le traitement du cancer
HUT72558A (en) Defective adenovirus vectors and use thereof in gene therapy
AU2006092A (en) Recombinant virus expressing carcinoembryonic antigen and methods of use thereof
FR2718150B1 (fr) Virus recombinants, préparation et utilisation en thérapie génique.
BRPI0107737B1 (pt) vírus do herpes simplex 1 (hsv1), uso do hsv1, e, composição farmacêutica
AU2905199A (en) Combined therapy with a chemotherapeutic agent and an oncolytic virus for killing tumor cells in a subject
NZ220771A (en) Vaccine composition against herpes simplex virus type 1 and type 2 including as active agent hsv-2 envelope protein gd-2
AU1927797A (en) Vectors based on recombinant defective viral genomes, and their use in the formulation of vaccines
ZA949103B (en) Recombinant viruses and their use in gene therapy
SI0679717T1 (en) Soluble interferon -receptor, its preparation and use
MY137303A (en) Methods for treating proliferative diseases
Gershon et al. The varicella vaccine. Clinical trials in immunocompromised individuals
WO1997026918A3 (fr) Therapie par promedicament a enzyme dirige par ligand
FR2717495B1 (fr) Virus recombinants, préparation et utilisation en thérapie génique.
Renecker Bioenergetics and behavior of moose (Alces alces) in the aspen-dominated boreal forest
FR2717496B1 (fr) Virus recombinants, préparation et utilisation en thérapie génique.
JPS6488392A (en) Human body position detecting device
FR2717823B1 (fr) Virus recombinants, préparation et utilisation en thérapie génique.
Sebesta et al. ERCP and balloon dilation is a valuable alternative to surgical biliodigestive anastomosis in the long common channel syndrome in childhood
Burke Islam in the Sudan; the impact of religion, and religious elites, on development.
FR2717497B1 (fr) Virus recombinants, préparation et utilisation en thérapie génique.
OUCHI Some informal remarks on the M-form society
EP0373658A3 (fr) Utilisation de dérivés de la quinoline pour le traitement du cancer
McKeown The electron test accelerator: safety in design and operation